Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Proterris

Proterris
2012 FOUNDED
PRIVATE STATUS
Series A LATEST DEAL TYPE
$2M LATEST DEAL AMOUNT
4 INVESTORS
Description

Developer of clinical-development stage therapeutic applications intended to focus on inhaled and small-molecule carbon monoxide. The company's applications include demonstrated anti-fibrotic, anti-inflammatory and cytoprotective properties, enabling patients to avail CO for delayed graft function (DGF) in renal transplant recipients and idiopathic pulmonary fibrosis (IPF).

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Therapeutic Devices
Other Industries
Biotechnology
Pharmaceuticals
Primary Office
  • 33 Broad Street
  • Boston, MA 02109
  • United States
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Proterris’s full profile, request a free trial.

Proterris Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series A) 16-Aug-2019 $2M 000 0000 Completed Clinical Trials - Phase 2
3. Early Stage VC (Series A) 09-May-2017 Completed Startup
2. Grant $22.7M Completed Startup
1. Accelerator/Incubator Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Proterris Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series A 0,000,000 00.000000 00 00.00 00.00 00 00.00 0.00
To view this company’s complete Cap Table, request access »

Proterris Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000 04-May-2017 000000000000000000 Biotechnology 0000000 00000 00
To view this company’s complete investment and acquisition history, request access »

Proterris Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Columbia Technology Ventures University Minority 000 0000 000000 0
Portugal Ventures Venture Capital Minority 000 0000 000000 0
Johns Hopkins Technology Ventures Accelerator/Incubator 000 0000 000000 0
National Institutes of Health Government 000 0000 000000 0

Proterris Executive Team (5)

Name Title Board
Seat
Contact
Info
Jeffrey Wager MD Co-Founder, Chairman & Chief Executive Officer
Benjamin Perrone Chief Financial Officer & Director, Finance and Business Development
Joseph Wager Co-Founder, Vice President, Business Development and Board Observer
Augustine Choi MD Co-Founder
Kourosh Saeb-Parsy Ph.D Acting Chief Medical Officer

Proterris Board Members (4)

Name Representing Role Since Contact
Info
Donald DeBethizy Ph.D Self Board Member 000 0000
Jeffrey Wager MD Proterris Co-Founder, Chairman & Chief Executive Officer 000 0000
Matthew Bennett JD Self Board Member 000 0000
Peter Hutt JD Self Board Member 000 0000